%0 Journal Article
%A Recher, Christian
%A Roellig, Christoph
%A Berard, Emilie
%A Bertoli, Sarah
%A Dumas, Pierre-Yves
%A Tavitian, Suzanne
%A Kramer, Michael
%A Serve, Hubert
%A Bornhaeuser, Martin
%A Platzbecker, Uwe
%A Mueller-Tidow, Carsten
%A Baldus, Claudia D.
%A Martinez-Cuadron, David
%A Serrano, Josefina
%A Martinez-Sanchez, Pilar
%A Rodriguez Arboli, Eduardo
%A Gil, Cristina
%A Bergua, Juan
%A Bernal, Teresa
%A de la Fuente Burguera, Adolfo
%A Delabesse, Eric
%A Bidet, Audrey
%A Pigneux, Arnaud
%A Montesinos, Pau
%T Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
%D 2021
%@ 0887-6924
%U https://hdl.handle.net/10668/25507
%X The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients >= 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P = 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P
%K Acute myeloid-leukemia
%K Newly-diagnosed aml
%K Epigenetic therapy
%K Elderly-patients
%K Early death
%K Azacitidine
%K Management
%K Venetoclax
%K Regimens
%K Care
%~